Pantoprazole

Proton pump inhibitors

ATC code: A02BC02

Updated 24 Sep 2026 · Methodology

Indications

Gastroesophageal reflux disease

First line

First-line GERD therapy. PPIs are the most effective agents for acid suppression. Pantoprazole 40 mg once daily 30 minutes before breakfast. Course 4–8 weeks, then attempt dose reduction or on-demand dosing.

Sources

ACG: ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (2022)
Cochrane Database Syst Rev: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. (2013)
AEMPS: Ficha técnica PANTOPRAZOL STADA 40 mg COMPRIMIDOS GASTRORRESISTENTES EFG (2023)

ICD-10: K21 · ICD-11: DA22

NSAID gastropathy prophylaxis

First line

First-line prophylaxis of gastropathy in patients on long-term NSAIDs with risk factors – age over 65, ulcer history, concomitant anticoagulants or corticosteroids. Pantoprazole 20 mg once daily for the duration of NSAID therapy.

Sources

ICD-10: K31 · ICD-11: DA60.62

Peptic ulcer disease

First line

First-line for peptic ulcer disease. Duodenal ulcer course is 4 weeks, gastric ulcer 8 weeks. In H. pylori eradication, any PPI at double dose twice daily. Pantoprazole is preferred in patients on clopidogrel after coronary stenting.

Sources

ICD-10: K25 · ICD-11: DA60

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

PPI for NSAID gastric prophylaxis in low-risk patients

Not recommended

Pantoprazole is a proton pump inhibitor (PPI). It is prescribed for GERD, peptic ulcer, Helicobacter pylori eradication, and gastroprotection with NSAID use in patients at high GI bleeding risk – age over 65, ulcer history, concomitant anticoagulants or corticosteroids ( 2022, 2020). In low-GI-bleeding-risk patients on short-term NSAIDs, routine PPI gastroprotection is not justified: long-term PPI use is linked to specific risks – vitamin B12 and magnesium deficiency, elevated risk of intestinal infections (Clostridioides difficile), pneumonia, hip and vertebral fractures (via impaired calcium absorption), and chronic kidney disease. If pantoprazole was prescribed for long-term use without confirmed high GI risk, consider seeking a second opinion.

Sources

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

Irreversibly inhibits H+/K+-ATPase (proton pump) in gastric parietal cells. Same mechanism as omeprazole. A distinctive feature of pantoprazole is its weaker CYP2C19 inhibition. This underpinned the 2009 caution about omeprazole–clopidogrel interaction, but the clinical relevance has been refuted by the COGENT RCT (Bhatt DL et al. NEJM 2010) and subsequent studies: no difference in cardiovascular outcomes between DAPT patients on different PPIs. Pantoprazole remains a reasonable choice in clopidogrel-treated patients, but this is no longer a critical advantage.

Safety

Contraindications

Hypersensitivity to PPIs

Serious adverse effects

Clostridioides difficile-associated diarrhea
Hypomagnesemia with long-term use (over 1 year)
Increased fracture risk with long-term use – hip, wrist, spine
Vitamin B12 deficiency with use over 2 years
Acute interstitial nephritis (rare)

Common adverse effects

Headache
Diarrhea
Nausea
Flatulence
Abdominal pain

Pregnancy: can you take Pantoprazole?

AEMPS summary of product characteristics (section 4.6): data from 300–1,000 pregnancies show no malformative or fetal/neonatal toxicity, but animal studies showed reproductive toxicity. As a precaution, pantoprazole is not recommended during pregnancy.

Breastfeeding: can you take Pantoprazole?

Compatible. Hale L2. Transfers into milk in small amounts (RID about 1%); infant gastric acid inactivates the molecule before meaningful systemic absorption. AEG and AAP consider it compatible; a nursing mother on reflux or ulcer therapy can continue breastfeeding. The infant may show mild functional gut symptoms (flatulence, stool changes) that usually resolve on their own.

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Take 30 minutes before the first meal. The proton pump is activated by meal-stimulated signaling, and the drug needs to be circulating at that point. Swallow the tablet whole, do not crush – the enteric coating protects against degradation in gastric acid.

Special situations

In vitro, pantoprazole is a weaker CYP2C19 inhibitor than omeprazole or esomeprazole. This was the historical basis of the 's 2009 caution on the clopidogrel interaction, but the COGENT RCT (Bhatt DL et al. NEJM 2010) and subsequent studies have shown no clinically meaningful difference in cardiovascular outcomes between PPIs in DAPT patients. Current position: PPIs are indicated during dual antiplatelet therapy to reduce GI bleeding; the choice of molecule is not critical. Pantoprazole remains a convenient option in clopidogrel-treated patients, especially when other CYP2C19-sensitive drugs are involved.

Drug–drug interactions

4 pairs found. Sorted from critical to minor.

MajorMethotrexateAntimetabolites, folic acid analogues

Mechanism

Proton pump inhibitors block the renal BCRP transporter, reducing methotrexate clearance. At high oncologic doses: risk of severe delayed toxicity.

Symptoms

Mouth ulcers (mucositis), nausea, diarrhoea, hair loss. Blood counts fall: leukocytes, platelets, erythrocytes. Severe cases: fatal pancytopenia, nephrotoxicity.

Management

At oncologic methotrexate doses, stop pantoprazole 5 days before and resume 5 days after dosing. Alternative: famotidine (H2-blocker, no BCRP effect). At low rheumatologic doses, pantoprazole is acceptable.

Sources

Pair details →Methotrexate →

ModerateAtorvastatinHMG-CoA reductase inhibitors (statins)

Mechanism

Pantoprazole is the most CYP-neutral PPI. No clinically significant interaction with statins.

Symptoms

No changes.

Management

The combination is acceptable without dose change. Pantoprazole is the preferred PPI in patients on statins and other CYP3A4-dependent drugs.

Sources

FDA: Lipitor (atorvastatin) prescribing information (2017)

Pair details →Atorvastatin →

ModerateCyanocobalaminVitamins. Haemopoietic stimulants

Mechanism

Pantoprazole reduces gastric acidity and B12 release from food. With long-term therapy, B12 deficiency risk is reported, similar to other PPIs.

Symptoms

Fatigue, pallor, paraesthesias in hands and feet, gait instability, memory decline. Develops over 2–4 years of unrecognised therapy.

Management

On long-term pantoprazole (over 2 years), check B12 yearly. Cyanocobalamin can be given regardless of acidity (passive diffusion absorption at high doses). For sustained acid suppression, consider dose reduction or periodic breaks.

Sources

PubMed: Metformin use and vitamin B12 deficiency: a systematic review and meta-analysis (2020)

Pair details →Cyanocobalamin →

MinorClopidogrelAntiplatelet agents – P2Y12 receptor inhibitors

Mechanism

Clopidogrel is a prodrug that needs CYP2C19 for activation, and its label lists the inhibitors to avoid: omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine and efavirenz. Pantoprazole is not on that list, which is why it serves as the compatible PPI when the stomach needs protection without losing antiplatelet effect.

Symptoms

The combination produces no symptoms of its own. What is watched is bleeding from the antiplatelet itself: black stools, bruising, gum bleeding. A long PPI course adds hypomagnesaemia and lower vitamin B12, unrelated to clopidogrel.

Management

If a patient on clopidogrel needs a proton pump inhibitor, pantoprazole is suitable: the clopidogrel SmPC approved by the European Medicines Agency () states that clopidogrel can be given with pantoprazole, and the pantoprazole label approved by the US Food and Drug Administration () requires no clopidogrel dose change. Omeprazole and esomeprazole are avoided with clopidogrel (clopidogrel SmPC, EMA; clopidogrel label, FDA).

Sources

Pair details →Clopidogrel →

Label mentions44 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

MajorAtazanavir
«Inhibidores de la proteasa del VIH: No se recomienda la administración conjunta de pantoprazol e inhibidores de la proteasa del VIH, tales como atazanavir, debido a que se produce una reducción…»
AEMPS, section 4.5 · Open on CIMA
ModerateFluvoxamine
«Otros estudios de interacciones: Los inhibidores de la enzima CYP2C19 como la fluvoxamina pueden aumentar la exposición sistémica al pantoprazol. Se debe considerar una reducción en la dosis para los…»
AEMPS, section 4.5 · Open on CIMA
ModerateMethotrexate
«Metotrexato: Se ha notificado que el uso concomitante de altas dosis de metotrexato (ej. 300 mg) e inhibidores de la bomba de protones, incrementa los niveles de metotrexato en algunos pacientes. Por…»
AEMPS, section 4.5 · Open on CIMA
Amoxicillin
«Otros estudios de interacciones: También se han realizado estudios de interacción administrando pantoprazol de forma concomitante con antibióticos (claritromicina, metronidazol y amoxicilina). No se…»
AEMPS, section 4.5 · Open on CIMA
antiácidosclass named in the label
«Otros estudios de interacciones: No se presentaron tampoco interacciones con antiácidos administrados concomitantemente.»
AEMPS, section 4.5 · Open on CIMA
anticoagulantesclass named in the label
«Anticoagulantes cumarínicos (fenprocumon o warfarina): La administración concomitante de pantoprazol con fenprocumón o warfarina no afecta a la farmacocinética de la warfarina, del fenprocumon o a la…»
AEMPS, section 4.5 · Open on CIMA
anticonceptivos hormonalesclass named in the label
«Otros estudios de interacciones: Los estudios de interacción con medicamentos que se metabolizan igualmente mediante estas rutas metabólicas, como carbamazepina, diazepam, glibenclamida, nifedipino y…»
AEMPS, section 4.5 · Open on CIMA
antifúngicos azólicosclass named in the label
«Medicamentos con farmacocinética de absorción dependiente del pH: Debido a la profunda y larga duración de la inhibición de la secreción ácida gástrica, pantoprazol puede interferir en la absorción…»
AEMPS, section 4.5 · Open on CIMA
Atazanavir
«DRUG INTERACTIONS: Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known…»
FDA, section 7 · Open on DailyMed
Caffeine
«Otros estudios de interacciones: Los resultados de estudios sobre un registro de interacciones demuestran que pantoprazol no afecta el metabolismo de sustancias activas metabolizadas mediante las…»
AEMPS, section 4.5 · Open on CIMA
Carbamazepine
«Otros estudios de interacciones: Los estudios de interacción con medicamentos que se metabolizan igualmente mediante estas rutas metabólicas, como carbamazepina, diazepam, glibenclamida, nifedipino y…»
AEMPS, section 4.5 · Open on CIMA
Clarithromycin
«Otros estudios de interacciones: También se han realizado estudios de interacción administrando pantoprazol de forma concomitante con antibióticos (claritromicina, metronidazol y amoxicilina). No se…»
AEMPS, section 4.5 · Open on CIMA
Clopidogrel
«DRUG INTERACTIONS: Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known…»
FDA, section 7 · Open on DailyMed
Diazepam
«Otros estudios de interacciones: Los estudios de interacción con medicamentos que se metabolizan igualmente mediante estas rutas metabólicas, como carbamazepina, diazepam, glibenclamida, nifedipino y…»
AEMPS, section 4.5 · Open on CIMA
Diclofenac
«Otros estudios de interacciones: Los resultados de estudios sobre un registro de interacciones demuestran que pantoprazol no afecta el metabolismo de sustancias activas metabolizadas mediante las…»
AEMPS, section 4.5 · Open on CIMA
Digoxin
«Otros estudios de interacciones: Los resultados de estudios sobre un registro de interacciones demuestran que pantoprazol no afecta el metabolismo de sustancias activas metabolizadas mediante las…»
AEMPS, section 4.5 · Open on CIMA
Ethinylestradiol
«Otros estudios de interacciones: Los estudios de interacción con medicamentos que se metabolizan igualmente mediante estas rutas metabólicas, como carbamazepina, diazepam, glibenclamida, nifedipino y…»
AEMPS, section 4.5 · Open on CIMA
Glibenclamide
«Otros estudios de interacciones: Los estudios de interacción con medicamentos que se metabolizan igualmente mediante estas rutas metabólicas, como carbamazepina, diazepam, glibenclamida, nifedipino y…»
AEMPS, section 4.5 · Open on CIMA
Itraconazole
«Medicamentos con farmacocinética de absorción dependiente del pH: Debido a la profunda y larga duración de la inhibición de la secreción ácida gástrica, pantoprazol puede interferir en la absorción…»
AEMPS, section 4.5 · Open on CIMA
Itraconazole
«DRUG INTERACTIONS: Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known…»
FDA, section 7 · Open on DailyMed
Ketoconazole
«Medicamentos con farmacocinética de absorción dependiente del pH: Debido a la profunda y larga duración de la inhibición de la secreción ácida gástrica, pantoprazol puede interferir en la absorción…»
AEMPS, section 4.5 · Open on CIMA
Ketoconazole
«DRUG INTERACTIONS: Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known…»
FDA, section 7 · Open on DailyMed
Levonorgestrel
«Otros estudios de interacciones: Los estudios de interacción con medicamentos que se metabolizan igualmente mediante estas rutas metabólicas, como carbamazepina, diazepam, glibenclamida, nifedipino y…»
AEMPS, section 4.5 · Open on CIMA
Methotrexate
«DRUG INTERACTIONS: Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known…»
FDA, section 7 · Open on DailyMed
Metoprolol
«Otros estudios de interacciones: Los resultados de estudios sobre un registro de interacciones demuestran que pantoprazol no afecta el metabolismo de sustancias activas metabolizadas mediante las…»
AEMPS, section 4.5 · Open on CIMA
Metronidazole
«Otros estudios de interacciones: También se han realizado estudios de interacción administrando pantoprazol de forma concomitante con antibióticos (claritromicina, metronidazol y amoxicilina). No se…»
AEMPS, section 4.5 · Open on CIMA
Mycophenolate mofetil
«DRUG INTERACTIONS: Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known…»
FDA, section 7 · Open on DailyMed
Naproxen
«Otros estudios de interacciones: Los resultados de estudios sobre un registro de interacciones demuestran que pantoprazol no afecta el metabolismo de sustancias activas metabolizadas mediante las…»
AEMPS, section 4.5 · Open on CIMA
Nifedipine
«Otros estudios de interacciones: Los estudios de interacción con medicamentos que se metabolizan igualmente mediante estas rutas metabólicas, como carbamazepina, diazepam, glibenclamida, nifedipino y…»
AEMPS, section 4.5 · Open on CIMA
Posaconazole
«Medicamentos con farmacocinética de absorción dependiente del pH: Debido a la profunda y larga duración de la inhibición de la secreción ácida gástrica, pantoprazol puede interferir en la absorción…»
AEMPS, section 4.5 · Open on CIMA
Rifampicin
«Otros estudios de interacciones: Los medicamentos inductores de las enzimas CYP2C19 y CYP3A4 como la rifampicina y la hierba de San Juan ( Hypericum perforatum ) pueden reducir las concentraciones…»
AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

Clopidogrel
«Se han observado reducciones menos pronunciadas de la exposición al metabolito con pantoprazol o lansoprazol.»
AEMPS, section 4.5 · Open on CIMA
Clopidogrel
«CYP2C19 Inhibitors: Avoid concomitant use of clopidogrel with omeprazole or esomeprazole. In clinical studies, omeprazole was shown to reduce significantly the antiplatelet activity of clopidogrel…»
FDA, section 7 · Open on DailyMed
Dabigatran
«Sustancias que influyen en el pH gástrico: Pantoprazol»
AEMPS, section 4.5 · Open on CIMA
Diazepam
«Inhibidores enzimáticos: El inhibidor de la bomba de protones, omeprazol, inhibidor de CYP3A4 y CYP2C19, administrado a dosis de 20 mg al día incrementa el AUC de diazepam en un 40% y la semivida en…»
AEMPS, section 4.5 · Open on CIMA
Dronedarone
«Otra información: Pantoprazol (40 mg una vez al día), un medicamento que incrementa en pH gástrico sin efecto alguno sobre el citocromo P450, no interacciona significativamente con la farmacocinética…»
AEMPS, section 4.5 · Open on CIMA
Lactoferrin
«La absorción del hierro puede incrementarse por la administración simultánea de 200 mg de ácido ascórbico y reducirse con la administración simultánea de antiácidos, colestiramina o inhibidores de la…»
AEMPS, section 4.5 · Open on CIMA
Methotrexate
«Inhibidores de la bomba de protones: La administración concomitante de inhibidores de la bomba de protones, como el omeprazol o el pantoprazol, puede dar lugar a interacciones: la administración…»
AEMPS, section 4.5 · Open on CIMA
Mycophenolate mofetil
«Antiácidos e inhibidores de la bomba de protones (IBPs): Se observó un descenso en la exposición del MPA cuando antiácidos, como hidróxidos de magnesio y aluminio, e IBPs, incluyendo lansoprazol y…»
AEMPS, section 4.5 · Open on CIMA
Mycophenolate mofetil
«Effect of Other Drugs on Mycophenolate Mofetil: Examples Lansoprazole, pantoprazole»
FDA, section 7 · Open on DailyMed

Showing 40 of 44, heaviest first

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Pantoprazole used for?

Pantoprazole is evaluated for the following indications with varying evidence strength: NSAID gastropathy prophylaxis (evidence tier A), Peptic ulcer disease (evidence tier A), Gastroesophageal reflux disease (evidence tier A). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Pantoprazole?

Common side effects of Pantoprazole (≥ 1 in 100): Headache, Diarrhea, Nausea, Flatulence, Abdominal pain. See the Safety section for uncommon and serious reactions.

Is Pantoprazole safe during pregnancy?

Is Pantoprazole compatible with breastfeeding?

Who should not take Pantoprazole?

Pantoprazole is contraindicated in: Hypersensitivity to PPIs. Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMA
EMALabel dated 06/12/2009
FDA / DailyMedLabel dated 02/03/2025

Other drugs in this group

Rabeprazole, Slippery elm (inner bark), Almagate, Deglycyrrhizinated licorice (DGL), Famotidine, Mastic gum, Esomeprazole, Lansoprazole